

**Entities that paid for Thalomid or Revlimid may be affected by,
and could get a payment from, a new class action settlement.**

A federal Court authorized this Notice. It is not a solicitation from a lawyer.

- A new (March 2020) settlement has been reached with Celgene Corporation (“Celgene”) in a class action lawsuit about whether it acted to keep generic versions of Thalomid and Revlimid off the market. This Notice is for:
 - **Third-Party Payors (e.g., insurers, employee welfare benefits plans, and government funded employee welfare benefit plans) that paid for Thalomid or Revlimid.**
- Celgene has agreed to settle the lawsuit for \$34 million.
- You may be included in this settlement if you are a Third-Party Payor that paid for all or some of the purchase price of Thalomid or Revlimid in any form—for your members, employees, insureds, participants, or beneficiaries—in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before May 20, 2020.
- Your rights are affected whether you act or don’t act. Read this Notice carefully.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A CLAIM FORM DEADLINE: OCTOBER 15, 2020	Unless you or your entity already submitted a claim, this is the only way you will receive any payment from the settlement with Celgene. If you submitted a claim to participate in the 2019 class action settlement with Celgene, you do not need to, but you can, submit a supplemental claim for additional purchases made from August 1, 2019 through May 20, 2020. You will also give up the right to sue Celgene in a separate lawsuit about the claims this settlement resolves.
ASK TO BE EXCLUDED DEADLINE: SEPTEMBER 15, 2020	If you decide to exclude your entity, you will keep the right to sue Celgene in a separate lawsuit about the claims this settlement resolves, but you give up the right to get a payment from this settlement. This is the only option that allows your entity to sue, continue to sue, or be part of another lawsuit against Celgene related to the legal claims released by this settlement.
OBJECT TO THE SETTLEMENT DEADLINE: SEPTEMBER 15, 2020	If you do not exclude your entity from the settlement, you may object to it by writing to the Court about why you don’t like the settlement.
GO TO A HEARING ON: SEPTEMBER 30, 2020	You may object to the settlement and ask the Court for permission to speak at the Fairness Hearing about your objection.
DO NOTHING	If your entity is a Settlement Class Member (<i>see</i> Questions 5 and 6, below), your entity is automatically part of the settlement. If you do nothing, you will not get a payment from this settlement (unless you previously submitted a Claim Form) and you will give up the right to sue, continue to sue, or be part of another lawsuit against Celgene for any claim made in this lawsuit or released by the Settlement Agreement. If you submitted a claim in 2019, your claim will automatically be evaluated for eligibility to receive a payment if the proposed settlement is approved.

- These rights and options—and the deadlines to exercise them—are explained in this Notice.
- The Court in charge of this case still has to decide whether to approve the settlement.

BASIC INFORMATION ----- PAGE 3

1. Why was this Notice issued?
2. What is this lawsuit about?
3. What is a class action?
4. Why is there a settlement?

WHO IS INCLUDED IN THE SETTLEMENT ----- PAGE 3

5. How do I know whether my entity is part of the settlement?
6. Are there exceptions to being included?
7. What if I am still not sure whether my entity is part of the settlement?

THE SETTLEMENT BENEFITS—WHAT YOU GET IF YOU QUALIFY ----- PAGE 4

8. What does the settlement provide?
9. How much will my entity's payment be?
10. Why is there a new settlement with Celgene about Thalomid and Revlimid?

HOW TO GET A SETTLEMENT PAYMENT—SUBMITTING A CLAIM FORM ----- PAGE 4

11. How does my entity get a payment?
12. When would my entity get its payment?
13. What if my entity's name or address changes after I submit a Claim Form, but before it receives payment?
14. What rights are my entity giving up to get a payment and stay in the Settlement Class?
15. What are the Released Claims?

EXCLUDING YOUR ENTITY FROM THE SETTLEMENT ----- PAGE 5

16. How do I get my entity out of the settlement?
17. If I exclude my entity, will it still get a payment from this settlement?
18. If I do not exclude my entity, can it sue Celgene for the same claims later?

THE LAWYERS REPRESENTING YOU ----- PAGE 6

19. Does my entity have a lawyer in this case?
20. How will the lawyers be paid?

OBJECTING TO THE SETTLEMENT ----- PAGE 6

21. How do I tell the Court that my entity does not like the settlement?
22. May I come to Court to speak about my entity's objection?
23. What is the difference between objecting to the settlement and asking to be excluded from it?

THE COURT'S FAIRNESS HEARING ----- PAGE 7

24. When and where will the Court decide whether to approve the settlement?
25. Do I have to come to the hearing?
26. May I speak at the hearing?

IF YOU DO NOTHING ----- PAGE 7

27. What happens if I do nothing at all?

GETTING MORE INFORMATION ----- PAGE 7

28. How do I get more information?

BASIC INFORMATION

1. Why was this Notice issued?

A federal Court authorized this Notice because you have a right to know about the proposed settlement of this class action lawsuit and about all of your options before the Court decides whether to grant final approval to the settlement. This Notice explains the lawsuit, the settlement, your legal rights, what benefits are available, and who can get them.

Judge Madeline Cox Arleo of the United States District Court for the District of New Jersey is overseeing this class action. The case is known as *In re Thalomid and Revlimid Antitrust Litigation*, Case No. 2:14-cv-06997. The individuals and entities that filed this lawsuit are called the “Plaintiffs” and the company they sued, Celgene Corporation (“Celgene”), is called the “Defendant.”

2. What is this lawsuit about?

The lawsuit is about the prescription drugs Thalomid and Revlimid. Plaintiffs claim that Celgene acted to delay the availability of less expensive generic versions of the drugs. The Plaintiffs claim that these actions denied uninsured consumers, insured consumers, and third-party payors (“TPPs”), like insurers that paid for Thalomid and Revlimid, the benefits of competition and caused them to pay higher prices for these drugs than they otherwise would have.

The Defendant denies all of the claims and allegations made in the lawsuit.

3. What is a class action?

In a class action, one or more people or entities called Class Representatives or Plaintiffs sue on behalf of other people or entities with similar claims. The people and entities included in the class action are called a Class or Class Members. One court resolves the issues for all Class Members, except for those who exclude themselves from the Class.

The Class Representatives in this lawsuit are International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund, the City of Providence, International Union of Operating Engineers Local 39 Health and Welfare Trust Fund, The Detectives’ Endowment Association, New England Carpenters Health Benefits Fund, and David Mitchell.

4. Why is there a settlement?

The Court did not decide in favor of the Plaintiffs or Defendant. Instead, the Plaintiffs and Defendant agreed to a settlement. This way, they avoid the cost and burden of a trial and the people and entities allegedly affected can get benefits. The Class Representatives and their attorneys think the settlement is best for all Settlement Class Members.

WHO IS INCLUDED IN THE SETTLEMENT

5. How do I know whether my entity is part of the settlement?

The settlement includes both consumers and TPPs. TPPs are included in the settlement if they paid for some or all of the purchase price of Thalomid or Revlimid (for use by their members, employees, insureds, participants, or beneficiaries) in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before May 20, 2020, and are not listed as excluded from the settlement in Question 6. Members, employees, insureds, participants, or beneficiaries must have been located in one of these states *or* requested to have the prescription filled while located in one of these states, *or* your billing department must have been located in one of these states, *or* the pharmacy to which payments were made must have been located in one of these states.

Consumers are also included in the settlement if they purchased or paid for some or all of the purchase price of Thalomid or Revlimid (for personal or family use) in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before May 20, 2020.

Together, the consumers and TPPs described above are called “Settlement Class Members.”

6. Are there exceptions to being included?

Yes. The settlement does not include: (1) Celgene and its officers, directors, management, employees, parents, subsidiaries, or Affiliates; (2) federal or state governmental entities, except cities, towns, or municipalities with self-funded prescription drug plans; (3) persons or entities who only purchased Revlimid or Thalomid for purposes of resale directly from Celgene or its Affiliates; (4) fully insured health plans; (5) stop-loss insurers; (6) the judges in this Action and any members of their immediate families; and (7) the excluded entities listed in the table appearing on pages 8-10 of this Notice.

7. What if I am still not sure whether my entity is part of the settlement?

If you are not sure whether your entity is included, call 1-866-446-1551, go to www.ThalomidRevlimidLitigation.com, or write to one of the lawyers listed in Question 19 below.

THE SETTLEMENT BENEFITS—WHAT YOU GET IF YOU QUALIFY

8. What does the settlement provide?

A \$34 million Settlement Fund has been established by Celgene in this settlement. After deducting Court-approved attorneys' fees and expenses, and the costs of settlement notice and administration, 5.5% of the net Settlement Fund will be made available to Settlement Class Members who purchased Thalomid, of which 15.5% will be allocated to consumer Settlement Class Members and 84.5% will be allocated to TPP Settlement Class Members. The remaining 94.5% of the net Settlement Fund will go to Revlimid purchasers, of which 13.5% will be made available to consumer Settlement Class Members and 86.5% will be made available to TPP Settlement Class Members. This allocation is based on Plaintiffs' expert's damage calculations.

9. How much will my entity's payment be?

Your entity's share of the net Settlement Fund will depend on the total amount of money it spent on qualifying purchases of Thalomid and Revlimid and the total amount of money other TPP Settlement Class Members—that file a valid Claim Form—spent on qualifying purchases of Thalomid and Revlimid. All TPP Settlement Class Members will receive their share of the allotted net Settlement Fund in proportion to their total dollars spent. You are not responsible for calculating the amount your entity may be entitled to receive under the settlement. This calculation will be determined based on the information you provide on your Claim Form and the supporting documentation you submit.

A copy of the Plan of Allocation, which details how payments will be calculated, is available at www.ThalomidRevlimidLitigation.com.

10. Why is there a new settlement with Celgene about Thalomid and Revlimid?

Celgene originally entered into a settlement with a class of Thalomid and Revlimid purchasers in 2019, but it exercised its right to rescind that settlement under the terms of that settlement agreement. That settlement agreement no longer exists; this settlement replaces that one. If your entity submitted a claim to participate in the 2019 settlement, you do not need to submit a new claim to participate in this settlement.

HOW TO GET A SETTLEMENT PAYMENT—SUBMITTING A CLAIM FORM

11. How does my entity get a payment?

If your entity submitted a claim to participate in the 2019 Thalomid/Revlimid settlement, you do not need to submit a new Claim Form. The Settlement Administrator will use the Claim Form you previously submitted to calculate the amount you are owed. If you wish to correct your claim or if you have made additional purchases of Thalomid or Revlimid since submitting your claim, you may submit a Supplemental Claim Form to include those purchases. If your entity did not previously submit a claim, you must complete and submit a Claim Form by **October 15, 2020**. If you received this Notice in the mail and you previously submitted a claim, please see the enclosed Supplemental Claim Form to verify the records and add any additional purchases made from August 1, 2019 through May 20, 2020. Claims may be submitted online or downloaded for printing and submission via U.S. Mail at www.ThalomidRevlimidLitigation.com. Claim Forms and instructions are also available by calling 1-866-446-1551 or by writing to *In re Thalomid and Revlimid Antitrust Litigation* Settlement Administrator, P.O. Box 43508, Providence, RI 02940-3508.

12. When would my entity get its payment?

The Court will hold a hearing at 2:00 p.m. on September 30, 2020 to decide whether to grant final approval to the settlement. If the Court approves the settlement, there may be appeals. It is always uncertain whether appeals will be filed and, if so, how long it will take to resolve them. The net Settlement Fund will be distributed to Settlement Class Members as soon as possible, if and when the Court grants final approval to the settlement.

13. What if my entity's name or address changes after I submit a Claim Form, but before it receives payment?

If your entity's name or address needs to be corrected, you must send a letter to the Settlement Administrator, *In re Thalomid and Revlimid Antitrust Litigation* Settlement Administrator, P.O. Box 43508, Providence, RI 02940-3508.

14. What rights is my entity giving up to get a payment and stay in the Settlement Class?

Unless you exclude your entity, it is staying in the Settlement Class. If the settlement is approved and becomes final, all of the Court's orders will apply to your entity and legally bind it. Your entity won't be able to sue, continue to sue, or be part of any other lawsuit against Celgene and certain related parties for any claim made in this lawsuit or released by the Settlement Agreement, but it will be able to submit a Claim Form to receive a payment from this settlement. The rights your entity is giving up are called Released Claims.

15. What are the Released Claims?

Generally, if and when the Settlement Agreement becomes final, Settlement Class Members will permanently release Celgene—and its predecessors, successors, subsidiaries, parents, affiliates, divisions, and departments (including but not limited to the Bristol-Myers Squibb Company)—and each of their respective officers, directors, employees, agents, attorneys, servants, and representatives, and the predecessors, successors, heirs, executors, administrators, and assigns of each of the foregoing (the “Released Parties”) from any and all claims, counterclaims, demands, actions, potential actions, suits, and causes of action, losses, obligations, damages, matters and issues of any kind or nature whatsoever, and liabilities of any nature, including without limitation claims for costs, expenses, penalties, and attorneys’ fees, whether class, individual, or otherwise, that the Settlement Class Members, their predecessors, successors, subsidiaries, parents, affiliates, divisions, and departments, and each of their respective officers, directors, employees, agents, attorneys, servants, and representatives, and the predecessors, successors, heirs, executors, administrators, and assigns of each of the foregoing, ever had or now has directly, representatively, derivatively or in any other capacity against any of the Released Parties, whether known or unknown, suspected or unsuspected, asserted or unasserted, foreseen or unforeseen, actual or contingent, accrued or unaccrued, matured or unmatured, disclosed or undisclosed, apparent or unapparent, liquidated or unliquidated, or claims that have been, could have been, or in the future might be asserted in law or equity, on account of or arising out of or resulting from or in any way related to any conduct regardless of where it occurred at any time prior to the Effective Date (the date on which all of the following have occurred: (1) the Settlement Agreement is approved by the Court; (2) the Court enters a final approval order, entering a final judgment of dismissal with prejudice against Plaintiffs and members of the Settlement Class who have not timely excluded themselves from the Settlement Class; and (3) the time for appeal or to seek permission to appeal from the Court’s approval of the Settlement Agreement and entry of a final judgment has expired or, if appealed, approval of the Settlement Agreement and the final judgment has been affirmed in its entirety by the court of last resort and the appeal is no longer subject to further appeal or review) concerning the purchase, reimbursement for and/or payment for some or all of the purchase price for Thalomid or Revlimid in any form, including without limitation, claims based in whole or in part on the facts, occurrences, transactions, or other matters alleged in the Action, or otherwise the subject of the Action, which arise under any antitrust, unfair competition, unfair practices, price discrimination, unitary pricing, trade practice, consumer protection, unjust enrichment, civil conspiracy law, or any other law, code, rule, or regulation of any country or jurisdiction worldwide, including under federal or state law, and regardless of the type or amount of damages claimed, from the beginning of time through the Effective Date.

Settlement Class Members will not release any claims for product liability, breach of warranty, breach of contract, or tort of any kind (other than a breach of contract, breach of warranty or tort based on any factual predicate in this action), a claim arising out of violation of Uniform Commercial Code, or personal or bodily injury.

The specific claims your entity will be releasing are described in paragraph 23 of the Settlement Agreement, available at www.ThalomidRevlimidLitigation.com.

EXCLUDING YOUR ENTITY FROM THE SETTLEMENT

If you want your entity to keep the right to sue or continue to sue Celgene for any claim made in this lawsuit or released by the Settlement Agreement, and your entity does not want to receive a payment from this settlement, you must take steps to get out of the settlement. This is called excluding your entity from, or opting out of, the settlement.

16. How do I get my entity out of the settlement?

TPPs that want to be excluded from the Settlement Class must email and mail a written request for exclusion to the Settlement Administrator. Your request for exclusion must include: (1) the entity name and address; (2) the name of the entity representative; (3) the name of this case, *In re Thalomid and Revlimid Antitrust Litigation*, Case No. 2:14-cv-06997; (4) a statement, signed by an authorized representative, that your entity is a Settlement Class Member and you wish for it to be excluded from the Settlement Class; (5) data sufficient to establish your entity’s relevant Thalomid and Revlimid purchases or payments, measured in number of prescriptions, number of pills, and dollars paid by the entity, and aggregated on a monthly basis for each of Thalomid and Revlimid, and each state in which the relevant purchases or payments were made. Exclusion requests must be emailed and mailed to the Settlement Administrator at the postal and email addresses below and postmarked no later than **September 15, 2020**:

In re Thalomid and Revlimid Antitrust Litigation
Settlement Administrator
P.O. Box 43508
Providence, RI 02940-3508
info@thalomidrevlimidlitigation.com

A separate exclusion request must be filed by each TPP electing to be excluded from the Settlement Class. Any TPP included in the Settlement Class that does not submit a valid request for exclusion providing all necessary information will be bound by the terms of the settlement.

17. If I exclude my entity, will it still get a payment from this settlement?

No. If you exclude your entity, you are telling the Court that it does not want to be part of the Settlement Class in this settlement. Your entity can only get a payment if it stays in the Settlement Class and submits a Claim Form.

18. If I do not exclude my entity, can it sue Celgene for the same claims later?

No. Unless you exclude your entity, you are giving up the right to sue Celgene for the claims that this settlement resolves. You must exclude your entity from *this* lawsuit to start or continue with your own lawsuit or be part of any other lawsuit against Celgene.

THE LAWYERS REPRESENTING YOU

19. Does my entity have a lawyer in this case?

Yes. Judge Arleo appointed Hausfeld LLP, Block & Leviton LLP and Hach Rose Schirripa & Cheverie LLP to represent your entity and other Settlement Class Members as “Settlement Class Counsel.” These law firms and their lawyers are experienced in handling similar cases. You will not be charged for these lawyers. If you want to be represented by your own lawyer, you may hire one at your own expense.

20. How will the lawyers be paid?

Settlement Class Counsel will ask the Court for attorneys’ fees of up to 33 and one-third percent of the \$34 million Settlement Fund, and reimbursement of their expenses (up to \$4 million). The Court may award less than these amounts. All of these amounts, as well as the costs associated with administering the settlement and service awards to the Class Representatives (\$10,000 each, if approved), will be paid from the Settlement Fund before making payments to Settlement Class Members who submit valid Claim Forms.

The application for an award of attorneys’ fees and reimbursement of costs and expenses will be filed with the Clerk of the United States District Court for the District of New Jersey, Martin Luther King Building & U.S. Courthouse, 50 Walnut Street, Room 4015, Newark, New Jersey 07101. After it is filed, it will also be available at www.ThalomidRevlimidLitigation.com.

OBJECTING TO THE SETTLEMENT

You can tell the Court if your entity does not agree with the settlement or any part of it.

21. How do I tell the Court that my entity does not like the settlement?

If you are a TPP Settlement Class Member, your entity can object to the settlement if you do not like it or a portion of it (including the request for attorneys’ fees and costs—see Question 20). You can give reasons why you think the Court should not approve it. The Court will consider your views. To object, you must send a letter via First Class U.S. Mail saying that your entity objects to the settlement of *In re Thalomid and Revlimid Antitrust Litigation*, Case No. 2:14-cv-06997. Your objection must also include: (1) your entity’s name; (2) address; (3) telephone number; (4) signature; (5) a statement indicating that your entity is a member of the TPP Settlement Class and is not listed in the table as excluded; and (6) the reasons why your entity objects to the settlement. Email and mail your objection to info@thalomidrevlimidlitigation.com and all three addresses below postmarked on or before **September 15, 2020**.

Clerk of the Court	Settlement Class Counsel	Defense Counsel
Clerk of the United States District Court for the District of New Jersey Martin Luther King Building & U.S. Courthouse 50 Walnut Street, Room 4015 Newark, NJ 07101	Melinda R. Coolidge Hausfeld LLP 1700 K Street, NW Suite 650 Washington, DC 20006 mcoolidge@hausfeld.com	John E. Schmidlein Williams & Connolly LLP 725 12th Street, NW Washington, DC 20005 JSchmidlein@wc.com

22. May I come to Court to speak about my entity’s objection?

Yes. You or your entity’s attorney may speak at the Fairness Hearing about your objection. To do so, in addition to the information above, your objection must also include: (1) a statement that it is your “Notice of Intention to Appear in front of Judge Arleo at the Fairness Hearing in *In re Thalomid and Revlimid Antitrust Litigation*, Case No. 2:14-cv-06997”; (2) an outline of your positions and the reasons for them; and (3) copies of any supporting documents or briefs you want the Court to consider. Remember, your objection must be postmarked by **September 15, 2020** and sent to all three addresses in Question 21.

23. What is the difference between objecting to the settlement and asking to be excluded from it?

Objecting is simply telling the Court that your entity doesn't like something about the settlement. Your entity can object only if it stays in the Settlement Class (do not exclude your entity). Excluding your entity is telling the Court that it does not want to be part of the Settlement Class. If you exclude your entity, it cannot object because the settlement no longer affects it.

THE COURT'S FAIRNESS HEARING

The Court will hold a hearing to decide whether to approve the settlement. You may attend and you may ask to speak, but you don't have to.

24. When and where will the Court decide whether to approve the settlement?

The Court will hold a Fairness Hearing at 2:00 p.m. on September 30, 2020 at the United States District Court for the District of New Jersey, Martin Luther King Building & U.S. Courthouse, 50 Walnut Street, Newark, New Jersey 07101. At this hearing, the Court will consider whether the settlement is fair, reasonable and adequate. It will also consider whether to approve: (1) the amount and proposed distribution of the Settlement Fund; (2) Settlement Class Counsel's application for an award of attorneys' fees and disbursement of expenses and costs; and (3) the service awards to be paid to the Class Representatives. If there are objections, the Court will consider them. Judge Arleo will listen to people who have asked to speak at the hearing (*see* Question 22 above). After the hearing, the Court will decide whether to approve the settlement.

25. Do I have to come to the hearing?

No. Settlement Class Counsel will answer any questions Judge Arleo may have. However, you are welcome to come to the hearing at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but that is not necessary.

26. May I speak at the hearing?

Yes. You may ask the Court for permission to speak at the Fairness Hearing (*see* Question 22 above).

IF YOU DO NOTHING

27. What happens if I do nothing at all?

If you are a TPP Settlement Class Member and you do nothing, your entity will give up the rights explained in Question 15, including your right to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Celgene for any claim made in this lawsuit or released by the Settlement Agreement. In addition, your entity will not receive a payment (unless you previously submitted a Claim Form) from the net Settlement Fund.

GETTING MORE INFORMATION

28. How do I get more information?

This Notice summarizes the proposed settlement. Complete details are provided in the Settlement Agreement. The Settlement Agreement and other related documents are or will be available by: (1) writing to one of the law firms listed in Question 19; (2) going to www.ThalomidRevlimidLitigation.com; or (3) writing to the Settlement Administrator, *In re Thalomid and Revlimid Antitrust Litigation* Settlement Administrator, P.O. Box 43508, Providence, RI 02940-3508. Publicly-filed documents can also be obtained by visiting the office of the Clerk of the United States District Court for the District of New Jersey or reviewing the Court's online docket.

Excluded Entities

A

Accountable Care Options, LLC,
c/o MSP Recovery Claims, Series LLC
Aetna, Inc.
Aetna, Inc. Self-Funded Groups
All Savers Insurance Co.
All Savers Life Insurance Co. of California
AmeriChoice of New Jersey, Inc.
AMERIGROUP Community Care of New Mexico,
Inc.
AMERIGROUP District of Columbia, Inc.
AMERIGROUP Florida, Inc.
AMERIGROUP Insurance Co. (TX)
AMERIGROUP Iowa, Inc.
AMERIGROUP IPA of New York, LLC
AMERIGROUP Kansas, Inc.
AMERIGROUP Louisiana, Inc.
AMERIGROUP Maryland, Inc.
AMERIGROUP Nevada, Inc.
AMERIGROUP New Jersey, Inc.
AMERIGROUP Partnership Plan, LLC
AMERIGROUP Tennessee, Inc.
AMERIGROUP Texas, Inc.
AMERIGROUP Washington, Inc.
AMGP Georgia Managed Care Co., Inc.
Anthem Blue Cross Life and Health Insurance Co.
Anthem Health Plans, Inc.
Anthem Health Plans of Kentucky, Inc.
Anthem Health Plans of Maine, Inc.
Anthem Health Plans of New Hampshire, Inc.
Anthem Health Plans of Virginia, Inc.
Anthem, Inc.
Anthem, Inc. Self-Funded Group
Anthem Insurance Companies, Inc.
Anthem Kentucky Managed Care Plan, Inc.
Arizona Physicians IPA, Inc.
ATH Holding Co., LLC
AvMed, Inc., c/o MSP Recovery Claims, Series LLC

B

Better Health, Inc.
Blue Cross and Blue Shield Association
Blue Cross and Blue Shield of Florida, Inc.
Blue Cross and Blue Shield of Florida, Inc. Self-
Funded Groups
Blue Cross and Blue Shield of Georgia, Inc.
Blue Cross and Blue Shield of North Carolina
Blue Cross and Blue Shield of North Carolina Self-
Funded Groups
Blue Cross and Blue Shield of Rhode Island
Blue Cross and Blue Shield of Rhode Island Self-
Funded Groups
Blue Cross and Blue Shield of Vermont
Blue Cross and Blue Shield of Vermont Self-Funded
Groups
Blue Cross Blue Shield Healthcare Plan of Georgia,
Inc.
Blue Cross Blue Shield of Kansas City
Blue Cross Blue Shield of Kansas City Self-Funded
Groups
Blue Cross Blue Shield of Massachusetts

I

Independent Health
Interamerican Medical Center Group LLC,
c/o MSP Recovery Claims, Series LLC

M

MAMSI Life and Health Insurance Company
Matthew Thornton Health Plan, Inc.
MCCI Group Holdings, LLC, c/o MSP Recovery Claims,
Series LLC
MD-Individual Practice Association, Inc.
Medica HealthCare Plans, Inc.
Medica Health Plans of Florida, Inc.
Medical Consultants Management, LLC,
c/o MSP Recovery Claims, Series LLC
Medical IPA of the Palm Beaches, Inc.,
c/o MSP Recovery Claims, Series LLC
Medical Mutual
MVP Health Care
MVP Health Care Self-Funded Groups

N

National Pacific Dental, Inc.
Neighborhood Health Partnership, Inc.
Nevada Pacific Dental

O

Optimum Choice, Inc.
Optum360 Services, Inc.
OptumRx Group Holdings, Inc.
OptumRx, Inc.
Oxford Health Insurance, Inc.
Oxford Health Plans (CT), Inc.
Oxford Health Plans (NJ), Inc.
Oxford Health Plans (NY), Inc.

P

PacifiCare Life Assurance Company
PacifiCare Life and Health Insurance Company
PacifiCare of Arizona, Inc.
PacifiCare of Colorado, Inc.
PacifiCare of Nevada, Inc.
Peninsula Health Care, Inc.
Peoples Health, Inc.
Physician Access Urgent Care Group, LLC,
c/o MSP Recovery Claims, Series LLC
Physicians Health Choice of Texas, LLC
Priority Health Care, Inc.
Preferred Care Partners, Inc.
Preferred Medical Plan, Inc., c/o MSP Recovery Claims,
Series LLC
Preferred Primary Care, LLC, c/o MSP Recovery Claims,
Series LLC
Premera Blue Cross
Premera Blue Cross Self-Funded Groups
Priority Health
Priority Health Self-Funded Groups
Professional Health Choice, Inc., c/o MSP Recovery Claims,
Series LLC

R

Risk Watchers, Inc., c/o MSP Recovery Claims, Series LLC
Rocky Mountain HealthCare Options, Inc.
Rocky Mountain Health Maintenance Organization,
Incorporated

Blue Cross Blue Shield of Massachusetts Self-Funded Groups
Blue Cross Blue Shield of Minnesota
Blue Cross Blue Shield of Minnesota Self-Funded Groups
Blue Cross Blue Shield of Tennessee, Inc.
Blue Cross Blue Shield of Tennessee, Inc. Self-Funded Groups
Blue Cross Blue Shield of Wisconsin
Blue Cross of California
Blue Cross of California Partnership Plan, Inc.
Blue Shield of California
Blue Shield of California Self-Funded Groups
Biocon Limited
Broward Primary Partners, LLC,
c/o MSP Recovery Claims, Series LLC

C

CareFirst BlueChoice, Inc.
CareFirst of Maryland, Inc.
CareFirst of Maryland, Inc. BlueChoice Self-Funded Groups
Care Improvement Plus of Texas Insurance Company
Care Improvement Plus South Central Insurance Company
Care Improvement Plus Wisconsin Insurance Company
CareMore Health Plan
CareMore Health Plan of Nevada
CareMore, LLC
Centene Corporation
CFA, LLC
Cigna Health and Life Insurance Company
Cigna Health and Life Insurance Company Self-Funded Groups
Clinica Las Mercedes, c/o MSP Recovery Claims, Series LLC
Community Health Providers, Inc.,
c/o MSP Recovery Claims, Series LLC
Community Insurance Company
Compcare Health Services Insurance Corporation

D

Dental Benefit Providers of California, Inc.
Dental Benefit Providers of Illinois, Inc.

E

EmblemHealth
EmblemHealth Self-Funded Groups
Empire HealthChoice Assurance, Inc.
Empire HealthChoice HMO, Inc.

F

Fallon Community Health Plan, Inc.,
c/o MSP Recovery Claims, Series LLC
Family Physicians Group, Inc. d/b/a Family Physicians of Winter Park, Inc.,
c/o MSP Recovery Claims, Series LLC

G

Golden Rule Insurance Company
Government Employees Health Association
Group Health Inc., c/o MSP Recovery Claims, Series LLC
Group Hospitalization and Medical Services, Inc.

Rocky Mountain Hospital and Medical Service, Inc.

S

Sierra Health and Life Insurance Company, Inc.
Simply Healthcare Plans, Inc.
Symphonix Health Insurance, Inc.

T

Transatlantic Healthcare, LLC, c/o MSP Recovery Claims, Series LLC
Trinity Physicians, LLC, c/o MSP Recovery Claims, Series LLC
Tufts Associated Health Plans, Inc.
Tufts Associated Health Plans, Inc. Self-Funded Groups

U

UHC of California
UNICARE Health Insurance Company of Texas
UNICARE Health Insurance Company of the Midwest
UNICARE Health Plan of Kansas, Inc.
UNICARE Health Plan of West Virginia, Inc.
UNICARE Health Plans of Texas, Inc.
UNICARE Health Plans of the Midwest, Inc.
Unimerica Life Insurance Company of New York
Unison Health Plans of Delaware, Inc.
United HealthCare Services, Inc.
UnitedHealth Group Incorporated / Optum360 Services, Inc.
UnitedHealthcare Benefits of Texas, Inc.
UnitedHealthcare Benefits Plan of California
UnitedHealthcare Community Plan, Inc.
UnitedHealthcare Community Plan of California, Inc.
UnitedHealthcare Community Plan of Georgia, Inc.
UnitedHealthcare Community Plan of Ohio, Inc.
UnitedHealthcare Community Plan of Texas, Inc.
UnitedHealthcare Insurance Company
UnitedHealthcare Insurance Company of Illinois
UnitedHealthcare Insurance Company of New York
UnitedHealthcare Insurance Company of the River Valley
UnitedHealthcare Insurance Designated Activity Company
UnitedHealthcare Integrated Services, Inc.
UnitedHealthcare Life Insurance Company
UnitedHealthcare of Alabama, Inc.
UnitedHealthcare of Arizona, Inc.
UnitedHealthcare of Arkansas, Inc.
UnitedHealthcare of Colorado, Inc.
UnitedHealthcare of Florida, Inc.
UnitedHealthcare of Georgia, Inc.
UnitedHealthcare of Illinois, Inc.
UnitedHealthcare of Kentucky, Ltd.
UnitedHealthcare of Louisiana, Inc.
UnitedHealthcare of Mississippi, Inc.
UnitedHealthcare of New England, Inc.
UnitedHealthcare of New Mexico, Inc.
UnitedHealthcare of New York, Inc.
UnitedHealthcare of North Carolina, Inc.
UnitedHealthcare of Ohio, Inc.
UnitedHealthcare of Oklahoma, Inc.
UnitedHealthcare of Pennsylvania, Inc.
UnitedHealthcare of Texas, Inc.
UnitedHealthcare of the Mid-Atlantic, Inc.
UnitedHealthcare of the Midlands, Inc.
UnitedHealthcare of the Midwest, Inc.
UnitedHealthcare of Utah, Inc.
UnitedHealthcare of Washington, Inc.

H

Harken Health Insurance Company
Harvard Pilgrim Health Care, Inc.
Harvard Pilgrim Health Care, Inc. Self-Funded Groups
Hawaii Medical Service Association
Hawaii Medical Service Association Self-Funded Groups
Health Care Advisor Services, Inc.,
 c/o MSP Recovery Claims Series LLC
Health Care Service Corporation
Health Care Service Corporation Self-Funded Groups
Health First Health Plans, Inc.,
 c/o MSP Recovery Claims, Series LLC
Health Insurance Plan of Greater NY,
 c/o MSP Recovery Claims, Series LLC
HealthKeepers, Inc.
HealthPartners, Inc.
HealthPartners, Inc. Self-Funded Groups
Health Plan of Nevada, Inc.
HealthPlus, LLC
HealthSun Health Plans, Inc.
Healthy Alliance Life Insurance Company
Highmark Blue Cross Blue Shield
HMO Colorado, Inc.
HMO Missouri, Inc.
Horizon Blue Cross Blue Shield of New Jersey
Humana, Inc.
Humana, Inc. Self-Funded Groups
Hygea Health Holdings, Inc.,
 c/o MSP Recovery Claims, Series LLC

UnitedHealthcare of Wisconsin, Inc.
UnitedHealthcare Plan of the River Valley, Inc.
USABLE Mutual Insurance Company
 d/b/a Arkansas Blue Cross and Blue Shield

V

Verimed IPA, LLC, c/o MSP Recovery Claims, Series LLC
Vidamax Medical Center (Fictitious name) for St. Jude Medical Group Corp.,
 c/o MSP Recovery Claims, Series LLC

W

WellCare Health Plans, Inc.
WellCare Health Plans, Inc. Self-Funded Groups
Wellmark Blue Cross and Blue Shield
Wisconsin Collaborative Insurance Company